Daewoong Pharmaceutical Indonesia

Daewoong Highlights Cholesterol Management for Patients with Diabetes at PIT PERKENI 2026; Only 5 in 100 Patients at High Cardiovascular Risk Achieve Target Levels

Writer

Manager

June 27, 2026

- At the 2026 endocrinology conference, Daewoong highlights the importance of LDL-C management in patients with type 2 diabetes

- Only 4.9% of patients at high cardiovascular risk reached the recommended LDL-C level of less than 55 mg/Dl

- Symposium introduces ezetimibe/rosuvastatin combination therapy as a treatment option

‍

Daewoong Pharmaceutical Indonesia (Daewoong) held a scientific symposium titled “Comprehensive Lipid Management in Patients with Type 2 Diabetes” on June 27 in Bandung, Indonesia, at the 14th Annual Scientific Meeting of the Indonesian Society of Endocrinology (PIT PERKENI 2026), Indonesia’s largest endocrinology conference. Daewoong shared the local situation in which only 4.9% of patients at high cardiovascular risk in Indonesia reached the LDL-C target of less than 55 mg/dL, and highlighted the importance of lipid management, including LDL-C control, in patients with type 2 diabetes who are at high risk of cardiovascular disease.

Speakers and Daewoong representatives pose for a group photo after Daewoong’s media session on dyslipidemia held during PIT PERKENI 2026. From left to right: dr. Wicak Prasetiadi, Head of Brand & Marketing, Daewoong Pharmaceutical Indonesia; Baik In Hyun, Head of Indonesia Business Division, Daewoong Pharmaceutical; Seong-soo Park, CEO, Daewoong Pharmaceutical; Prof. Dr. dr. Sidartawan Soegondo, Sp.PD-KEMD, FINASIM, FACE, Senior Endocrinologist, University of Indonesia and Eka Hospital BSD; and Hyoung Cheol Park, Managing Director, Head of ETC Marketing Division, Daewoong Pharmaceutical.

‍

The three-day conference was held from June 26 to 28 at Hotel Aryaduta Bandung and was attended by approximately 500 medical professionals from across Indonesia, including endocrinologists, internists, residents, and researchers.

‍

At the symposium, participants discussed lipid-lowering strategies for patients who have difficulty reaching target levels with monotherapy alone. In particular, the symposium introduced ezetimibe/rosuvastatin combination therapy, which targets both cholesterol synthesis in the liver and cholesterol absorption in the intestine, as a key treatment option.

‍

Dyslipidemia, which is commonly observed in patients with type 2 diabetes, is a major factor in increasing the risk of cardiovascular complications. For this reason, diabetes care requires not only blood glucose control but also lipid management, including LDL-C management.

From left to right: 1) Prof. Da-hye Seo, MD, PhD, Endocrinologist, Division of Endocrinology, Inha University School of Medicine, South Korea; 2) Prof. Dr. dr. Sidartawan Soegondo, Sp.PD-KEMD, FINASIM, FACE, Senior Endocrinologist, Eka Hospital BSD, appeared as a speaker in the panel session of the Crezet Lunch Symposium, which was moderated by Dr. dr. Laksmi Sasiarini, SpPD, K-EMD.

‍

According to the World Heart Federation (WHF), cardiovascular disease caused 765,660 deaths in Indonesia in 2021. A multicenter registry study published in the Indonesian Journal of Cardiology in 2025 also found that among high- and very high-risk cardiovascular patients in Indonesia, only 4.9% achieved the LDL-C target of less than 55 mg/dL, while 21.2% achieved the target of less than 70 mg/dL.

‍

Local research has also shown that dyslipidemia is common among patients with type 2 diabetes. According to a 2025 study published in the Current Internal Medicine Research and Practice Surabaya Journal, dyslipidemia was identified in 74% of 100 patients with type 2 diabetes. Among 40 patients with both type 2 diabetes and coronary artery disease, 85% had dyslipidemia. These findings highlight the importance of managing dyslipidemia and cardiovascular risk together in patients with type 2 diabetes.

‍

Prof. Dr. dr. Sidartawan Soegondo, Sp.PD-KEMD, FINASIM, FACE, of Eka Hospital BSD, said, “In Indonesian clinical practice, patients with type 2 diabetes often present with multiple cardiovascular risk factors. Therefore, actively lowering LDL-C is an important therapeutic priority.

‍

To improve the low rate of LDL-C target achievement among high-risk patients, treatment strategies should be individualized and optimized according to each patient’s cardiovascular risk profile. Current international guidelines also consistently recommend the early initiation of evidence-based lipid-lowering therapy and rapid achievement of LDL-C targets.”

Prof. Dr. dr. Sidartawan Soegondo, Sp.PD-KEMD, FINASIM, FACE, Senior Consultant in Internal Medicine, Endocrinology, Metabolism, and Diabetes at Eka Hospital BSD, delivered a presentation titled “Dyslipidemia in the Era of Cardiovascular-Kidney-Metabolic Syndrome: The Importance of Optimal LDL Management” at PIT PERKENI 2026.

‍

Prof. Da Hea Seo, from the Division of Endocrinology at Inha University Hospital, Korea, who joined the symposium as an international speaker, said, “Managing dyslipidemia in patients with type 2 diabetes requires a comprehensive approach that includes LDL-C control. For patients who have difficulty reaching targets with monotherapy alone, combination therapy that simultaneously targets cholesterol synthesis and absorption may serve as a treatment option.”

Prof. Da-hye Seo, Professor in the Division of Endocrinology, Department of Internal Medicine, Inha University College of Medicine, delivered a presentation on strategies to optimize lipid management through ezetimibe and rosuvastatin combination therapy at PIT PERKENI 2026.

‍

Shawn Park, CEO of Daewoong Pharmaceutical, who attended the event, said, “Over the past 20 years, Daewoong has built deep trust with the Indonesian medical community and grown together as a partner. Beyond supplying medicines, we will provide treatment solutions needed by local patients with chronic diseases and contribute to improving Indonesia’s healthcare environment.”

‍

Daewoong plans to pursue joint research based on local patient clinical data to build clinical evidence optimized for Asian patients. The company will also continue collaboration between Korean and Indonesian medical professionals to support medical advancement in both countries and help improve the quality of local healthcare.

list

- At the 2026 endocrinology conference, Daewoong highlights the importance of LDL-C management in patients with type 2 diabetes

- Only 4.9% of patients at high cardiovascular risk reached the recommended LDL-C level of less than 55 mg/Dl

- Symposium introduces ezetimibe/rosuvastatin combination therapy as a treatment option

Privacy Policy

이용약관